News Center

BIOCENTURY | JAN 18, 2018 CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. Th...

HealthNewsDigest | Jan 20, 2019 According to the American Society for Gastrointestinal Endoscopy, colorectal cancer (aka colon cancer) is the second leading cause of cancer-related deaths in the Unite...

MD+DI | 01/09/2019 – CellMax Life has developed a blood test that it says can identify precancerous adenomas with similar accuracy as colonoscopy, which may facilitate better compliance with scr...

NEW YORK (GenomeWeb) – JAN 02, 2019 Sunnyvale, California-based CellMax Life said today that it has partnered with Taiwan-based Medigen Biotech as part of the firm’s cell therapy clinical trials. Medi...

CellMax Life said today its CMx™ circulating tumor cell (CTC) platform and liquid biopsy panel will be used by Medigen Biotech in upcoming clinical trials of its cell therapy candidates for cancers, w...

Patents cover entirety of sub-$200 test and platform, which isolates rare circulating tumor cells (CTCs) from one tube of blood CellMax Life, enabling early cancer detection and management with afford...

Chicago Tribune | June 27, 2018 — Medical tests save lives. Discovering diseases before they become more serious can mean the difference between life and death. But many Americans say they don’t have ...

Scientific American | June 20, 2018 — Colorectal Cancer Is on the Rise in Young Adults They’re reluctant to have invasive colonoscopies, but a simple blood test could improve compliance By Shai ...

MedTech Breakthrough Awards, 2018 — Leading Cancer Management Company Wins Prestigious Award for its Proprietary Circulating Tumor Cell (CTC) CMx Platform CellMax Life, a leading cancer detection and ...

Becker’s GI & Endoscopy | May 30, 2018  Cancer diagnostics company CellMaxLife launched Zenith, the U.S. trial of its circulating tumor cell blood test to detect colorectal cancer. Here are ...

ASCO Reading Room 05.31.2018 — A new blood test appears to detect expression of the programmed death-ligand 1 (PD-L1) protein in circulating tumor cells (CTCs) with high sensitivity, enabling repeat t...

NEW YORK (360Dx) – CellMax Life announced this week that it is beginning a new clinical trial, which will further validate its circulating tumor cell (CTC) colorectal cancer screening test in American...

  SUNNYVALE, Calif., May 30, 2018 /PRNewswire/ — CellMax Life, a leading cancer diagnostics company enabling early cancer detection with affordable non-invasive blood tests, today announced...

May 2018 | Laboratory Economics CellMax Life (Sunnyvale, CA) has already been marketing its blood test for the early detection of colon cancer in Asia for the past two years and plans to o er it in th...

Apr 10, 2018 | NEW YORK (GenomeWeb) CellMax Life and IncellDx said today that they have signed an agreement to jointly develop and market circulating tumor cell tests across multiple solid tumors and ...

SUNNYVALE, CALIF. (PRWEB) MARCH 28, 2018 CellMax Life, a leading cancer diagnostics company enabling early cancer detection with affordable non-invasive blood tests, announced today the U.S. launch of...

Wall Street Journal, March 16, 2018 7:30 a.m. ET Theranos Inc.’s fall underscores the need for medical startups to be transparent in their dealings with investors and to publish data supporting their ...

This study showed that the CellMax CTC blood test can predict which patients in the gray zone will need/have a positive prostate biopsy with a much lower false positive rate than current standard of c...

A new, noninvasive blood test can reliably detect prostate cancer in patients with inconclusive PSA tests, the test’s developer, CellMax Life, recently announced. Researchers say the company’s circula...

Wall Street Journal highlights CellMax Life’s circulating tumor cell (CTC) as a proven blood testing platform to detect cancer early…. beyond standard DNA sequencing on the Illumina platfo...